Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

[1]  P. Laurent-Puig,et al.  Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  N. Ahuja,et al.  KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma , 2013, International journal of cancer.

[3]  M. Boubaya,et al.  Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4]  Seung‐Mo Hong,et al.  Combined loss of E-cadherin and aberrant β-catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas. , 2013, American journal of clinical pathology.

[5]  E. Van Cutsem,et al.  Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. E. Silva,et al.  Alterations of the TP53 Gene in Gastric and Esophageal Carcinogenesis , 2012, Journal of biomedicine & biotechnology.

[7]  J. Bosset,et al.  Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. , 2012, European journal of cancer.

[8]  S. Kopetz,et al.  A Population-Based Comparison of Adenocarcinoma of the Large and Small Intestine: Insights Into a Rare Disease , 2012, Annals of Surgical Oncology.

[9]  H. Grabsch,et al.  Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Laetitia Huiart,et al.  Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.

[11]  J. Fléjou,et al.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications , 2011, Cellular Oncology.

[12]  I. Sobhani,et al.  Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[14]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Donohue,et al.  A single-institution experience with 491 cases of small bowel adenocarcinoma. , 2010, American journal of surgery.

[16]  M. Sim,et al.  Small Bowel Adenocarcinoma: Understaged and Undertreated? , 2010, Annals of Surgical Oncology.

[17]  S. Kopetz,et al.  Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine , 2010, Acta oncologica.

[18]  S. Kopetz,et al.  Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine , 2009, British Journal of Cancer.

[19]  C. Ko,et al.  Small Bowel Cancer in the United States: Changes in Epidemiology, Treatment, and Survival Over the Last 20 Years , 2009, Annals of surgery.

[20]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Lepage,et al.  Incidence and Management of Primary Malignant Small Bowel Cancers: A Well-defined French Population Study , 2006, The American Journal of Gastroenterology.

[22]  Hanlin L. Wang,et al.  Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma , 2006, Modern Pathology.

[23]  B. Bonaz,et al.  Small Bowel Adenocarcinoma in Patients with Crohn's Disease Compared with Small Bowel Adenocarcinoma De Novo , 2005, Inflammatory bowel diseases.

[24]  J. Behrens.  The role of the Wnt signalling pathway in colorectal tumorigenesis. , 2005, Biochemical Society transactions.

[25]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[26]  Y. Yamashita,et al.  Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas , 2004, International journal of cancer.

[27]  R. Penzel,et al.  Mutational activation of the RAS‐RAF‐MAPK and the wnt pathway in small intestinal adenocarcinomas , 2004, Scandinavian journal of gastroenterology.

[28]  S. Olschwang,et al.  Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study , 2003, Journal of clinical pathology.

[29]  S. Y. Park,et al.  Expression of beta-catenin and E-cadherin in the adenoma-carcinoma sequence of the stomach. , 2003, Anticancer research.

[30]  Tsung-Teh Wu,et al.  Frequent CpG island methylation in serrated adenomas of the colorectum. , 2003, The American journal of pathology.

[31]  M. Nilbert,et al.  Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine , 2003, Cancer.

[32]  S. Kummar,et al.  Management of small bowel adenocarcinoma. , 2002, Oncology.

[33]  M. Leppert,et al.  Prognostic significance of p53 mutations in colon cancer at the population level , 2002, International journal of cancer.

[34]  M. Talamonti,et al.  Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. , 2002, Archives of surgery.

[35]  W. Bodmer,et al.  An insight into the genetic pathway of adenocarcinoma of the small intestine , 2002, Gut.

[36]  Masatoshi Watanabe,et al.  Combination Analysis of Genetic Alterations and Cell Proliferation in Small Intestinal Carcinomas , 2000, Digestive Diseases and Sciences.

[37]  Yusuke Nakamura,et al.  Molecular and biological analysis of carcinoma of the small intestine: β-catenin gene mutation by interstitial deletion involving exon 3 and replication error phenotype , 2000, American Journal of Gastroenterology.

[38]  L. Karnell,et al.  Adenocarcinoma of the small bowel , 1999 .

[39]  W. Bodmer,et al.  Genetic pathways in colorectal and other cancers. , 1999, European journal of cancer.

[40]  A. Neugut,et al.  The epidemiology of cancer of the small bowel. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  G. Thomas,et al.  Alternative genetic pathways in colorectal carcinogenesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Palazzo,et al.  Reciprocity between membranous and nuclear expression of β-catenin in colorectal tumours , 1997, Virchows Archiv.

[43]  E. Kaplan,et al.  The presence of K‐12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors , 1997, Cancer.

[44]  S. Shimizu,et al.  Mutations of the Ki‐ras, p53 and APC genes in adenocarcinomas of the human small intestine , 1997, International journal of cancer.

[45]  J. Howard,et al.  Adenocarcinoma of duodenum and ampulla of Vater: Clinicopathology study and expression of p53, c‐neu, TGF‐α, CEA, and EMA , 1996, Journal of surgical oncology.

[46]  C. Koebnick,et al.  Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. , 2004, Cancer letters.